Aardvark Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts with 12-month price forecasts for Aardvark Therapeutics stock have an average target of 31.5, with a low estimate of 21 and a high estimate of 50. The average target predicts an increase of 306.98% from the current stock price of 7.74.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$21	$31.5	$29	$50
Change	+171.32%	+306.98%	+274.68%	+545.99%

Analyst Ratings

The average analyst rating for Aardvark Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25
Strong Buy	1
Buy	3
Hold	0
Sell	0
Strong Sell	0
Total	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tim Anderson B of A Securities	B of A Securities	Strong Buy Maintains $22 → $26	Strong Buy	Maintains	$22 → $26	+235.92%	Mar 27, 2025
Brian Abrahams RBC Capital	RBC Capital	Buy Initiates $21	Buy	Initiates	$21	+171.32%	Mar 10, 2025
Josh Schimmer Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates $50	Buy	Initiates	$50	+545.99%	Mar 10, 2025
Michael Ulz Morgan Stanley	Morgan Stanley	Buy Initiates $29	Buy	Initiates	$29	+274.68%	Mar 10, 2025
Tim Anderson B of A Securities	B of A Securities	Strong Buy Initiates $22	Strong Buy	Initiates	$22	+184.24%	Mar 10, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-2.94

from -1.82

EPS Next Year

-2.88

from -2.94

Fiscal Year	FY 2022	FY 2023	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-
Revenue Growth	-	-	-	-	-
EPS	-3.49	-1.82	-2.94	-2.88	-3.21
EPS Growth	-	-	-	-	-
Forward PE	-	-	-	-	-
No. Analysts	-	-	5	5	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.